Concepedia

Selective immune suppression using interleukin-6 receptor inhibitors for management of immune-related adverse events

Faisal Fa’ak, Maryam Buni, Adewunmi Falohun, Huifang Lu, Juhee Song, Daniel H. Johnson, Chrystia M. Zobniw, Van Anh Trinh, Muhammad O. Awiwi, Nourel Hoda Tahon,

Journal for ImmunoTherapy of Cancer · 2023 · 84 citations · 59 references

DOIFull text

Open access

Abstract

Targeting IL-6R could be an effective approach to treat several irAE types without hindering antitumor immunity. This study supports ongoing clinical trials evaluating the safety and efficacy of tocilizumab (anti-IL-6R antibody) in combination with ICIs (NCT04940299, NCT03999749).

References

59

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

F. Stephen Hodi, Steven O’Day, David F. McDermott et al. · New England Journal of Medicine · 2010 · 14.9K citations · Full text

Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma

James Larkin, Vanna Chiarion‐Sileni, René González et al. · New England Journal of Medicine · 2015 · 8K citations · Full text

Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells

Estelle Bettelli, Yijun Carrier, Wenda Gao et al. · Nature · 2006 · 6.8K citations

, , +13

The Orphan Nuclear Receptor RORγt Directs the Differentiation Program of Proinflammatory IL-17+ T Helper Cells

Ivaylo I. Ivanov, Brent S. McKenzie, Liang Zhou et al. · Cell · 2006 · 5K citations · Full text

, , +9

Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial

Jonathan E. Rosenberg, Jean Hoffman‐Censits, Tom Powles et al. · The Lancet · 2016 · 3.7K citations · Full text

, , +8